Molecular Mechanisms of Programmed Cell Death and Tissue Inflammation

Fiohi Zin*

Department of Microbiology, Tokyo University of Science, Tokyo, Japan

Corresponding Author*

Fiohi Zin,

Department of Microbiology,

Tokyo University of Science,

Tokyo, Japan

E-mail: fiohi@ezweb.ne.jp

Received: 09-Feb-2024, Manuscript No. JBTW-24-131379; **Editor assigned:** 12-Feb-2024, PreQC No. JBTW-24-131379 (PQ); **Reviewed:** 26-Feb-2024, QC No. JBTW-24-131379; **Revised:** 04-Mar-2024, Manuscript No. JBTW-24-131379 (R); **Published:** 11-Mar-2024, DOI: 10.35248/2322-3308-13.2.010.

DESCRIPTION

Programmed cell death, also known as apoptosis, is a fundamental process essential for the maintenance of tissue homeostasis and the regulation of cellular populations within multicellular organisms [1,2]. It serves as a crucial mechanism to eliminate damaged, infected, or unnecessary cells, thereby ensuring proper development, tissue renewal, and immune responses. In recent decades, our understanding of programmed cell death has expanded significantly, shedding light on its intricate molecular pathways and its implications in health and disease [3].

Programmed cell death is a highly regulated process orchestrated by a complex exchange of signalling molecules, enzymes, and cellular organelles [4]. The activation of apoptosis can be triggered by a variety of intrinsic and extrinsic stimuli, including cellular stress, DNA damage, growth factor withdrawal, or immune signaling [5]. These triggers converge on a series of molecular pathways that culminate in the activation of caspases, a family of protease enzymes that execute the dismantling of the cell [6].

One of the characterisitic features of apoptosis is the orderly dismantling of cellular components, characterized by chromatin condensation, nuclear fragmentation and the formation of apoptotic bodies. These morphological changes serve to package the cell's contents in an orderly manner, preventing inflammation and tissue damage while facilitating their clearance by neighbouring cells or phagocytes. This ensures that cell death occurs in a controlled and non-inflammatory manner, minimizing the impact on surrounding tissues [7].

Importantly, apoptosis is not the only form of programmed cell death. In recent years, alternative modes of cell death have been identified, each with distinct molecular mechanisms and functional consequences. One such pathway is necroptosis, a programmed form of necrosis characterized by the activation of Receptor-Interacting Protein Kinases (RIPKs) and the formation of a necrosome complex. Unlike apoptosis, necroptosis results in the rapid and inflammatory cell lysis, triggering robust immune responses and tissue inflammation [8].

Another emerging form of programmed cell death is pyroptosis, which occurs in response to infection or cellular damage and is mediated by the activation of inflammatory caspases. Pyroptosis is characterized by the formation of large membrane pores, leading to cell swelling and eventual rupture. This release of cellular contents, including pro-inflammatory cytokines, serves to amplify immune responses and coordinate host defense against pathogens [9].

The intricate interplay between different forms of programmed cell death highlights the complexity of cellular decision-making processes and the versatility of cell fate determination. Moreover, dysregulation of programmed cell death pathways has been implicated in a wide range of human diseases, including cancer, neurodegenerative disorders, autoimmune diseases, and infectious diseases. For example, defects in apoptosis can lead to uncontrolled cell proliferation and tumour formation, while excessive or dysregulated cell death can contribute to tissue damage and inflammation in autoimmune diseases [10].

In the context of cancer, understanding the mechanisms underlying programmed cell death has profound implications for the development of novel therapeutic strategies. Targeting the apoptotic machinery represents a promising approach for cancer therapy, with numerous drugs designed to induce apoptosis in tumour cells or sensitize them to cytotoxic therapies [11].

Similarly, modulating other forms of programmed cell death, such as necroptosis or pyroptosis, has potential therapeutic value in various disease contexts. Inflammatory diseases characterized by excessive cell death, such as sepsis or inflammatory bowel disease, could benefit from strategies aimed at dampening necroptotic or pyroptotic pathways to mitigate tissue damage and inflammation. Conversely, enhancing these pathways may be beneficial in certain cancer contexts, where induction of inflammatory cell death could trigger anti-tumour immune responses.

REFERENCES

1. Banerjee, A, et al. "Effects of polystyrene micro/nanoplastics on liver cells based on particle size, surface functionalization, concentration and exposure period". *Sci Total Environ*. 2022;836:155621.
2. Bobori, DC, et al. "Differentiation in the expression of toxic effects of polyethylene-microplastics on two freshwater fish species: Size matters". *Sci Total Environ.* 2022;830:154603.
3. Chang, J, et al. "Adsorption behaviors and bioavailability of tetrabromobisphenol A in the presence of polystyrene microplastic in soil: effect of microplastics aging". *Environ Pollut*. 2023;334:122156.
4. Guru Murthy, GS, et al. "Incidence and survival of T-cell acute lymphoblastic leukemia in the United States". *Leuk Lymphoma*. 2019;60(5):1171-1178.
5. Marks, DI., and Rowntree C. "Management of adults with T-cell lymphoblastic leukemia. Blood", *Am. J. Hematol.* 2017;129(9):1134-1142.
6. Kozlowski, P, et al. "High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper CVAD chemotherapy in Sweden". *Eur. J. Haematol*. 2014;92(5):377-381.
7. DeAngelo, DJ, et al. "Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801". *Am. J. Hematol*. 2007;109(12):5136-5142.
8. Gokbuget, N, et al. "High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation". *Am. J. Hematol*. 2011;118(13):3504-3511.
9. Farhadfar, N, et al. "Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature". Hematol./*Oncol. Stem Cell Ther*. 2021;14(3):246-251.
10. Sander, CA, et al. "Lymphoblastic lymphoma presenting in cutaneous sites: A clinicopathologic analysis of six cases". *J Am Acad Dermatol*. 1991;25(6):1023-1031.
11. Ali, R, et al. "Leukaemia cutis in T cell acute lymphoblastic leukaemia". *Cytopathology*. 2006;17(3):158-161.